8-K Announcements
6Material company update
May 27, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 9, 2026·SEC
Mesa Laboratories, Inc.(MLAB)Earnings, Financials & Key Ratios
MLAB•NASDAQ
$102.56
84.8× P/E·Price updated Jul 6, 2026
SectorTechnologyIndustryTech Hardware & EquipmentSub-IndustryTest, Measurement and Inspection Equipment
AboutMesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.Show more
- Revenue$249M+3.4%
- EBITDA$42M+2.2%
- Net Income$7M+440.0%
- EPS (Diluted)1.21+436.1%
- Gross Margin63.53%+1.5%
- EBITDA Margin16.77%-1.1%
- Operating Margin7.43%+9.6%
- Net Margin2.69%+428.9%
- ROE3.88%+399.9%
MLAB Price & Volume
Mesa Laboratories, Inc. (MLAB) stock price & volume — 10-year historical chart
Loading chart...
Stagnant Revenue Growth Masks Persistent Margin Volatility
Investment Thesis • Updated 2026Q4
VerdictNeutral
Growth:Mixed
Profitability:Strained
Financial:Mixed
Cash Flow:Mixed
Primary Risk:Goodwill impairment and integration
Key Thesis Takeaways
- Mesa Laboratories faces a challenging transition period characterized by decelerating revenue growth of 2.6% in 2026Q4 and significant bottom-line pressure from high SG&A expenses.
- While the company has successfully reduced its total debt from $236.1 million in 2024Q3 to $90.1 million in 2026Q4, the erosion of retained earnings to a $185.7 million deficit raises concerns regarding long-term shareholder value creation.
- Investors should monitor the company's ability to convert its 73.2% gross margin into sustainable operating income, as current non-operating charges and stock-based compensation continue to obscure underlying profitability.
Verdict Logic
while the forward P/E of 11.30 appears attractive, the company's inability to maintain positive net income, which reached -$4.1 million in 2026Q4, warrants a cautious wait-and-see approach.
MLAB Growth Metrics
Mesa Laboratories, Inc. (MLAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.4%
5 Years13.22%
3 Years4.38%
TTM3.38%
Profit CAGR
10 Years-4.96%
5 Years15.44%
3 Years93.25%
TTM440.02%
EPS CAGR
10 Years-8.59%
5 Years13.59%
3 Years92.36%
TTM424.32%
Return on Capital
10 Years-1.61%
5 Years-8.26%
3 Years-14.2%
Last Year5.83%
MLAB Recent Earnings
Mesa Laboratories, Inc. (MLAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 27, 2026Metric
Actual
Est
EPS
$2.76+32.1%
$2.09
Rev
$64M-2.3%
$65M
Q1 2026
Feb 3, 2026Metric
Actual
Est
EPS
$3.07+119.3%
$1.40
Rev
$65M+3.0%
$63M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.76+12.8%
$1.56
Rev
$61M-0.5%
$61M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$2.32-5.7%
$2.46
Rev
$60M-1.4%
$60M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 27, 2026 | $2.76vs $2.09+32.1% | $64Mvs $65M-2.3% |
| Q1 2026 | Feb 3, 2026 | $3.07vs $1.40+119.3% | $65Mvs $63M+3.0% |
| Q4 2025 | Nov 6, 2025 | $1.76vs $1.56+12.8% | $61Mvs $61M-0.5% |
| Q3 2025 | Aug 5, 2025 | $2.32vs $2.46-5.7% | $60Mvs $60M-1.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Mesa Laboratories, Inc. (MLAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $102.56 | $566.64M | 84.76 | 3.38% | 2.69% | 3.88% | 0.62% | |
| $9.51 | $2.07B | -1.89 | -3.2% | -69.93% | -29% | — | |
| $422.02 | $10.67B | -145.52 | 8.92% | -1.61% | -1.57% | — | |
| $164.89 | $5.87B | 112.17 | 3.3% | 5.35% | 5.08% | — | |
| $141.46 | $7.98B | 164.49 | 16.36% | 6.73% | 2.46% | — | |
| $52.47 | $12.43B | 29.98 | -2.61% | 12.37% | 7.95% | — |
Compare MLAB vs Peers
Mesa Laboratories, Inc. (MLAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MLAB SEC Filings & Documents
Mesa Laboratories, Inc. (MLAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MLAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MLAB Frequently Asked Questions
Mesa Laboratories, Inc. (MLAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Mesa Laboratories, Inc.'s revenue?
Mesa Laboratories, Inc. (MLAB) reported $249.1M in revenue for fiscal year 2026. This represents a 3094% increase from $7.8M in 1997.
How fast is Mesa Laboratories, Inc. growing?
Mesa Laboratories, Inc. (MLAB) grew revenue by 3.4% over the past year. Growth has been modest.
Is MLAB profitable?
Yes, Mesa Laboratories, Inc. (MLAB) is profitable, generating $6.7M in net income for fiscal year 2026 (2.7% net margin).
Dividend & Returns
Does MLAB pay dividends?
Yes, Mesa Laboratories, Inc. (MLAB) pays a dividend with a yield of 0.62%. This makes it attractive for income-focused investors.
What is MLAB's return on equity?
Mesa Laboratories, Inc. (MLAB) has a return on equity (ROE) of 3.9%. This is below average, suggesting room for improvement.
What is Mesa Laboratories, Inc.'s free cash flow?
Mesa Laboratories, Inc. (MLAB) generated $42.8M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.